Results 11 to 20 of about 16,768 (136)
Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
International Journal of Cancer, EarlyView.Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia +11 more
wiley +1 more source
Journal of Clinical Laboratory Analysis, EarlyView.This nationwide registry‐based study describes the clinical and molecular characteristics of 78 patients with transfusion‐dependent beta‐thalassemia in Spain. Comprehensive genetic analysis revealed marked molecular heterogeneity, with 24 HBB mutations identified and a predominance of β0 genotypes, alongside generally effective transfusion and iron ...
Ana Villegas +41 more
wiley +1 more source
Environmental Toxicology, EarlyView.ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó +9 more
wiley +1 more source
Andrology, EarlyView.ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino +5 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Although adult T‐cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366 ...
Bryan Valcarcel +31 more
wiley +1 more source
Age‐specific melanoma risk associated with nevi: a pooled analysis from the M‐SKIP project
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Objective This study investigates the association of melanoma risk with total‐body nevus count and the presence of atypical nevi in younger (< 40 years) and older (> 60 years) individuals. Methods A pooled analysis was conducted within the M‐SKIP project, based on multiple melanoma case‐control studies.
Giulia Doi +20 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To investigate the association of post‐oral glucose tolerance test (OGTT) hypoglycaemia with clinical features, incident diabetes and mortality. Materials and Methods This population‐based cohort study included 2924 adults (median age 49 years, 1680 women) without known diabetes who underwent a 75‐g OGTT as part of the Di@bet.es Study ...
Tomás González‐Vidal +14 more
wiley +1 more source
The FEBS Journal, EarlyView.Chd4/NuRD and ThPOK cooperate to maintain transcriptional repression and nuclear organization in adult cardiomyocytes. Chd4 loss reduces miR‐150‐5p, relieving repression of Sprr1a, while ThPOK loss further enhances Sprr1a activation, possibly through altered chromatin–lamina interactions.
Fadoua El Abdellaoui‐Soussi +12 more
wiley +1 more source
Italian Patients Journey for Gene Therapy in Haemophilia A
Haemophilia, EarlyView.ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno +19 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 7, Page 1597-1604, July 2026.ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo +38 more
wiley +1 more source